Stock Events

Stock Events

Avacta Group 

GBX71
64
-GBX1-1.39% Friday 16:23

Statistics

Day High
74
Day Low
69
52W High
84
52W Low
26
Volume
1,243,973
Avg. Volume
-
Mkt Cap
262.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16AprExpected
Q1 2023
Q2 2023
Q1 2024
Q2 2024
Q1 2025
Q2 2025
Next
-4.32
-2.89
-1.47
-0.05
Expected EPS
N/A
Actual EPS
N/A

Financials

-216.35%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
4.88BRevenue
-10.57BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AVCT.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides genomics solutions, competing in the biotechnology and diagnostics space similar to Avacta's focus on diagnostics and therapeutic solutions.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen is a major player in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, directly competing with Avacta's diagnostic technologies.
Bio-Rad Laboratories
BIO
Mkt Cap8.54B
Bio-Rad Laboratories offers products and systems used to separate complex chemical and biological materials, directly competing with Avacta's Affimer technology for life sciences research.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers a range of biotechnology product development services, including diagnostics and research, competing in the same space as Avacta.
Danaher
DHR
Mkt Cap152.13B
Danaher Corporation operates in the life sciences, diagnostics, and environmental industries, offering products and services that compete with Avacta's diagnostics and therapeutic solutions.
Repligen
RGEN
Mkt Cap8.39B
Repligen Corporation provides bioprocessing technologies and systems that are used in the production of monoclonal antibodies, competing with Avacta's proprietary Affimer platform for therapeutic use.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products, including diagnostics solutions that compete with Avacta.
Agenus
AGEN
Mkt Cap126.5M
Agenus Inc. is a biotechnology company focused on immunotherapy including immuno-oncology, a field that Avacta is also exploring with its Affimer technology.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies is involved in the immune-driven medicine space, offering products that compete with Avacta's diagnostics and research tools.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health operates in the precision oncology field, offering liquid biopsy tests that compete with Avacta's diagnostics solutions for cancer.

About

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Christina Marie Coughlin B.S., M.D., Ph.D.
Employees
151
Country
GB
ISIN
GB00BYYW9G87

Listings

F
DE
RTQ1.F
OTC Link
US
AVCTF
LSE
GB
AVCT.LSE

0 Comments

Share your thoughts

FAQ

What is Avacta Group stock price today?▼
The current price of AVCT.LSE is GBX71 GBX — it has decreased by -1.39% in the past 24 hours. Watch Avacta Group stock price performance more closely on the chart.
What is Avacta Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Avacta Group stocks are traded under the ticker AVCT.LSE.
Is Avacta Group stock price growing?▼
AVCT.LSE stock has risen by +9.23% compared to the previous week, the month change is a +27.93% rise, over the last year Avacta Group has showed a +82.05% increase.
What is Avacta Group market cap?▼
Today Avacta Group has the market capitalization of 262.28M
When is the next Avacta Group earnings date?▼
Avacta Group is going to release the next earnings report on April 16, 2026.
What were Avacta Group earnings last quarter?▼
AVCT.LSE earnings for the last quarter are -4.32 GBX per share, whereas the estimation was N/A GBX resulting in a N/A surprise. The estimated earnings for the next quarter are N/A GBX per share.
What is Avacta Group revenue for the last year?▼
Avacta Group revenue for the last year amounts to 4.88B GBX.
What is Avacta Group net income for the last year?▼
AVCT.LSE net income for the last year is -10.57B GBX.
How many employees does Avacta Group have?▼
As of March 16, 2026, the company has 151 employees.
In which sector is Avacta Group located?▼
Avacta Group operates in the Health Care sector.
When did Avacta Group complete a stock split?▼
The last stock split for Avacta Group was on January 26, 2016 with a ratio of 1:100.
Where is Avacta Group headquartered?▼
Avacta Group is headquartered in London, GB.